Exozymes (Ca) Inc.

Invizyne Technologies Inc. (doing business as a division of Exozymes Inc.) is a self-certified small disadvantaged business based in Monrovia, California, that develops cell-free biomanufacturing platforms and enzyme-engineering technologies for federal biomedical research and energy applications. The vendor operates as a grant recipient (83% of recent awards are prime grants) under the National Institutes of Health, the Department of Energy, and the National Science Foundation, with no federal contract prime footprint.

Invizyne's capability portfolio centers on cell-free enzymatic systems for synthesizing complex molecules without living cells. Representative work includes a $1,034,289 National Institute of General Medical Sciences project grant (CFDA 93.859) awarded July 2026 through June 2028 to develop SIMPLEPATH IIB, a pre-clinical research platform producing a library of cannabinoid analogs through a 7-enzyme cell-free system targeting therapeutic applications in glaucoma, inflammatory bowel disease, Huntington's disease, obesity, and chronic pain. A $283,805 NIGMS grant (CFDA 93.859) awarded April 2025 supports development of a cell-free, high-throughput platform for engineering enzymes for "BioClick" biocatalytic reactions using prenylation chemistry. A $496,177 Department of Energy Advanced Research Projects Agency grant (CFDA 81.135) awarded August 2022 focuses on simplifying cell-free biofuel production by reducing cofactor costs tenfold for isobutanol synthesis. Earlier work includes a cooperative agreement from DOE's Advanced Research Projects Agency on carbon-negative chemical synthesis using electrically powered cell-free biochemical pathways (October 2021 through September 2023) and a cooperative agreement from the Office of Energy Efficiency and Renewable Energy on energy-efficient cell-free isobutanol production (October 2023 through December 2025).

Customer concentration is concentrated in federal research funding agencies. The National Institute of General Medical Sciences leads with 4 awards, followed by the Advanced Research Projects Agency and the Office of Energy Efficiency and Renewable Energy with 2 awards each, and single awards from the National Science Foundation and the National Center for Complementary and Integrative Health, accounting for 83% of the award count. Invizyne also serves as a sub-recipient on two grants: a cell-free enzymatic cascades subtask under an NSF CFIRE grant managed by Georgia Tech Research Corporation (awarded October 2025) and protein-production work for cell-free biomanufactured aviation fuel as a subawardee under a Bioindustrial Manufacturing and Design Ecosystem grant (awarded July 2024). Activity is sparse and episodic — one award in both 2022 and 2023, two in 2024, two in 2025, and one in 2026 — with only one award facing completion in the next twenty-four months, reducing near-term recompete exposure.